{"prompt": "['Alliance A171601', '14.2.2 Objectives', 'To explore whether inherited genetic single nucleotide polymorphisms (SNPs) in', 'cell cycle pathway genes and in genes that metabolize palbociclib are associated', 'with efficacy and toxicity in elderly patients undergoing endocrine plus palbocic lib', 'therapy for estrogen receptor positive, HER2 negative metastatic breast cancer.', 'To explore whether SNPs in CYP19A1, CYP2A6 and ESRI will also correlate with', 'efficacy and toxicity in elderly patients undergoing endocrine plus palbociclib', 'treatment for estrogen receptor positive, HER2 negative metastatic breast cancer.', '14.2.3 Methods', 'Whole blood sample will be collected in 1 x10 mL EDTA vacutainer tube (purple top) from', 'patients at start of study for germline DNA isolation. Blood samples will be sent to a central', 'location at Mayo Clinic and DNA will be isolated in the Biospecimen Accessioning and', 'Processing (BAP) laboratory(submission instructions are in Section 6.2)', 'SNP selection Genotype data from the National Center for Biotechnology Information', '(NCBI) dbSNP database will be used with programs in National Institute of environmental', 'Health Sciences', 'Genome', 'variation', 'server', 'to derive tagged SNPs from the list of 18 genes', 'namely CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A,', 'CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D, CYP3A4, CYP19A1, CYP2A6,', 'ESR1, RB1 and SULT2A1. SNPs with allele frequencies 30% and r2 0.80 will be', 'selected for genotyping. Since only 88 patients will be accrued for the study, this minor', 'allele frequency (maf) cut offof 30% will ensure that we observe at least 10% of the patients', 'with a SNP of interest. It is important to indicate here that the overall sample number of 88', 'is low, therefore any associations may serve as hypothesis generating for larger study', \"numbers in the future. It is also important to note that there's ethnic variation in specific\", 'SNPs and their frequencies, therefore whenever the patient numbers are large enough to', 'obtain meaningful information on diverse populations, genotype information from the', 'database should reflect the patient population on the trial. The acquired tagSNPs (See', 'Appendix VIII) will be genotyped in the Genotyping Core of the Mayo Clinic Medical', 'Genome Facility (MGF) or in any Alliance associated genotyping core on either the', 'Sequenom or the Illumina GoldenGate custom array. A partial list of tag SNPs to be', 'genotyped is shown in the Table below:', 'Partial list of cell cycle pathway genes and SNPs to be genotyped', 'Alleles', 'Global Minor', 'Variant location/', 'allele', 'Gene', 'description', 'dbSNPrsid', 'function', 'Major', 'Minor', 'frequency', '(MAF)', 'CDK4', 'Cyclin dependent', 'rs 2069502', 'intron', 'C', 'T', '0.3367', 'kinase4', 'Cyclin dependent', 'CDK6', 'rs 2282978', 'intron', 'T', 'C', '0.3141', 'kinase 4', 'CCND1', 'cyclin D1', 's9344', 'synonymous codon', 'G', 'A', '0.413', 'CDKNIA', 'p21', 'rs 3176336', 'intron', 'T', 'A', '0.3678', 'CDKN1B', 'p27', '334330', '2KB upstream, 5UTR', 'C', 'T', '0.3383', 'CDKN2A', 'p16', 'rs 2811710', '500B downstream 3UTR', 'C', 'T', '0.4708', 'CDKN2B', 'p15', 'rs 3217992', '3UTR, intron', 'C', 'T', '0.3482', 'CDKN2D', 'p19', 'rs 1465701', 'intron', 'C', 'T', '0.4193', '70', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', 'Genotyping', 'The Agena iPLEX (previously called sequenom) genotyping protocol involves PCR', 'amplification of DNA using SNP specific primers, followed by a base extension reaction', 'using the iPLEX Gold chemistry (Agena Biosciences, San Diego, CA). The protocol has', 'been used for years and will briefly be described here. SNP-specific PCR and extension', 'primers were designed and organized into pools with the Assay Design Suite (Agena). All', 'primers were purchased from Integrated DNA Technologies (Coralville, IA). A QC run was', 'performed with Coriell and CEPH controls, and results were tested for Mendelian', 'inconsistencies. HotStar Taq Polymerase (Qiagen) was used for all PCRs. 15 ng of DNA', 'was added to each 5-ul PCR reaction mixture in a 384-well microtiter plate. The PCR', 'condition was 94\u00b0C for 15 min for hot start, followed by 45 cycles of denaturing at 94\u00b0C', 'for 20 sec, annealing at 56\u00b0C for 30 sec, extension at 72\u00b0C for 1 min for 45 cycles, and final', 'incubation at 72\u00b0C for 3 min. The PCR products were then treated with SAP (shrimp', 'alkaline phosphatase, Agena) for 40 min at 37\u00b0C then ramped to 85\u00b0C for 5 min to remove', 'excess dNTPs. The final base extension products were diluted in double distilled water and', 'then treated with 6mg of SpectroCLEAN (Agena) resin per well to remove contaminating', 'salts. 10-18 nl of treated extension product was spotted to the appropriate location on a 384-', 'pad SpectroCHIP II (Agena) using a RS1000 Nanodispenser (Agena, San Diego, CA). A', 'MassARRAY Analyzer Compact MALDI-TOF MS (Agena) was used for data acquisitions', 'from the SpectroCHIP. All resultant genotyping calls were performed in real time by the', 'MassARRAY Typer Analyzer v4.0.26.73 (Agena)', '14.2.4 Analyses', 'SNP analysis: Results from genotyping will be sent to the bioinformatics/statisticians for', 'analyses to correlate the SNPs with the primary objective of the study which is adverse', 'events. The SNPs will also be correlated to the secondary objectives which include toxicity,', 'response to treatment and overall survival.', '14.2.5 Hypotheses', '1. Patients with higher biomarker levels have an increased incidence of grade 3+ adverse', 'events.', '2. Patients with higher biomarker levels have higher rates of treatment modification', 'during adjuvant therapy.', '3. Patients with higher biomarker levels have poorer baseline performance status and', 'higher rates of performance status dec line during adjuvant therapy.', '14.2.6 Statistical analyses', 'Treatment modification is defined as any dose reduction or omission during the course of', 'the study. Biomarker levels will be compared to grade 3+ adverse event incidence (as', 'measured by the CTCAE version 5.0), rate of treatment modification, baseline performance', 'status and performance status throughout the course of the study descriptively and', 'graphically. Any testing done will be done in an exploratory manner.', '71', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}